Cryo-EM revealed HIV-1 integrase’s distinct structures as it shifts between its two roles of DNA integration and RNA-binding.

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Whether infection of cells by individual virions occurs randomly or if there is some form (s) of competition or cooperativity between individual virions remains largely unknown for most virus-cell ...

However, in the mid-1980s, as the AIDS epidemic raged and scientists desperately searched for a way to combat the newly ...

Atea Pharmaceuticals, Inc. ( AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements November 13, 2025 10:00 AM EST Jordan Feld Anthony Martinez Nancy Reau Eric ...

Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...

Q3 2025 Earnings Call November 12, 2025 4:30 PM ESTCompany ParticipantsJonae Barnes - Senior Vice President of ...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine have discovered how a ...

Despite the success of antiretroviral therapy (ART) in controlling HIV replication, a definitive cure remains elusive due to ...